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PreviewsATMs surrounding dying adipocytes
(Olefsky and Glass, 2010). B cells, being
antigen-presenting cells, can contribute
to ART activation and to pro- or anti-
inflammatory cytokine production, and
can modulate antibody responses, all of
which may impact the development of
obesity-induced insulin resistance.
Collectively, the Deng et al. study indi-
cates that during obesity, adipocytes
upregulate MHCII and act as antigen-pre-
senting cells to activate a Th1 response,
which is escalated by macrophages to
orchestrate adipose tissue inflammation
(Deng et al., 2013). These findings empha-
size the need to investigate the relative
contribution of different lymphocyte
subsets, ATMs, and adipocytes, as wellas their temporal relationship during
homeostasis or inflammatory skewing in
obesity.REFERENCES
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The human gut microbiome plays an important role in themetabolism of xenobiotics. In a recent issue ofCell,
Maurice et al. (2013) identify the active members of the gut microbiome and show how gene-expression
profiles change within the gut microbial community in response to antibiotics and host-targeted xenobiotics.Thenumerous anddiversemicrobes in the
gut (the gut microbiota) have long been
known to play key roles in breaking
down otherwise indigestible polysaccha-
rides and protecting the host against
pathogens through enzymatic pathways
encoded for in their microbial genes (the
microbiome) (Blaut, 2011; Sousa et al.,
2008). More recently, the gut microbiome
has been shown to play a role in the
metabolism of xenobiotics including anti-
biotics and drugs targeted against host
physiology: at least 30 commercially avail-
able drugs are metabolized as substrates
by bacterial enzymes (Clayton et al., 2009;
Sousa et al., 2008). The human gut’s
microbial community has been charac-
terized in both healthy and disease
states through 16S ribosomal RNA genesequencing, and Bacteroidetes has been
identified as the most abundant phylum
in most individuals (Clemente et al.,
2012; Human Microbiome Project Con-
sortium, 2012). However, this technique
cannot identify what portion of the gut
microbiome is metabolically active—and
its response to, and role in, xenobiotic
metabolism (Maurice et al., 2013).
To identify the metabolically active
members of the human gut microbiota,
Maurice et al. (2013) subjected fecal
samples to staining with propidium iodide
(Pi), DiBAC, and SybrGreen to identify
cells with a loss of membrane integrity,
membrane polarity, and high or low nu-
cleic acid content, respectively, and then
sorted the cells with FACS. Cells with
high nucleic acid content (HNA), repre-senting metabolically active microbes,
comprised 56.2% of the total (the remain-
ing low nucleic acid content [LNA] frac-
tion was assumed to be inactive). Nearly
a third of the gut microbiota had damage
through the loss of membrane integrity or
membrane polarity. The identity of the
microbes in these fractions was assessed
through 16S rRNA gene sequencing:
the HNA fraction was significantly en-
riched for Firmicutes, specifically Clostri-
diales, and depleted for Bacteroidales,
and the LNA fraction was enriched in
Bifidobacteriales. To confirm that the
gut harbors a distinct subset of metaboli-
cally active Clostridiales, fecal samples
from the same individual at two different
time points were analyzed using meta-
transcriptomics (RNA-seq). Significantly17, March 5, 2013 ª2013 Elsevier Inc. 317
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Previewshigher expression was seen from the
Firmicutes phylum relative to theBacteroi-
detes, and 15 taxonomic groups from the
Firmicutes exhibited expression levels
more than 4-fold higher than their gene
abundances would have predicted. The
metatranscriptomic analysis showed that
the active subset of the gut is enriched
for Firmicutes, rather than the physically
abundant Bacteroidetes phylum.
Consequently, understanding which
members of the gut microbiota are meta-
bolically active rather than simply numer-
ically dominant may be critical for predict-
ing individualized responses to drugs. The
gut microbiota’s response to antibiotics
targeted against the microbial community
was directly compared to drugs targeted
against the host. Exposure to a panel of
six different host-targeted xenobiotics
did not significantly alter microbial com-
munity structure. Subjecting the fecal
samples to a panel of eight different anti-
biotics, however, greatly affected micro-
bial community structure, increasing the
percentage of damaged cells in the gut
by more than 10%, although the metabol-
ically active HNA subset of Clostridiales
was unaffected. Different taxa responded
differently to different antibiotics, as
expected from previous studies (Dethlef-
sen and Relman, 2011): for example,
Faecalibacterium prausnitzii increased
4.5-fold following ampicillin treatment,
but decreased under pressure by other
antibiotics like ciprofloxacin and tetracy-
cline (Maurice et al., 2013).
What was not expected, however, was
the radically different transcriptional
responses in the surviving members of
the communities to host-targeted drugs
versus antibiotics. Changes in commu-
nity-wide gene expression were assessed
through RNA-seq following perturba-
tion by xenobiotics. Just as microbial
community structure is most similar
when comparing the same individual
at close time points, the transcriptional
profiles also clustered by individual
rather than by time point or treatment
(Caporaso et al., 2011; Maurice et al.,
2013), underscoring the individualized
nature of the microbiome and its tran-
scriptional activity. Nevertheless, across
individuals, host-targeted drugs signifi-
cantly increased expression of genes
involved in xenobiotic metabolism and
biodegradation, the pentose phosphate
pathway, and membrane transport, while318 Cell Metabolism 17, March 5, 2013 ª201antibiotics induced expression of genes
involved in phosphate transport, vitamin
biosynthesis, translation, and tRNA bio-
synthesis. Thus, researchers must con-
sider the possibility that the functional
profile of microbes that survive antibiotic
treatment might be different than their
pre-antibiotic selves.
Metatranscriptomics has the ability to
detect microbial contributions to pharma-
ceutical interventions that do not directly
result in changes in the microbial com-
munity structure. Maurice et al. (2013)
showed that 328 gene clusters were
differentially expressed after exposure to
host-targeted xenobiotics even though
these same drugs did not significantly
alter the microbial community structure.
Similarly, when humans, together with
mice harboring a defined 15 member
community, were dosed with commer-
cially available probiotics including strains
of Lactobacillus, Streptococcus thermo-
philus, and Bifidobacterium animalis
subsp. lactis, no appreciable changes
were seen in community structure as-
sessed through 16S rRNA sequencing,
yet metatranscriptomics revealed signifi-
cant changes in expression of genes
associated with carbohydrate and plant
polysaccharide metabolism (McNulty
et al., 2011). Gene expression, as well
as which species are present and active,
is thus likely to be critical for under-
standing a wide range of microbial pro-
cesses in the gut.
These changes in gene expression
are also important for understanding the
unintended interactions between host-
targeted drugs and the gut microbiome
that can lead to toxic effects. For
example, acetaminophen sulfonation is
significantly affected by the gut micro-
biota: microbial members that produce
high levels of p-cresol can greatly reduce
the host’s ability to sulfonate acetamino-
phen through competitive inhibition
(Clayton et al., 2009). These high levels
of endogenously produced p-cresol by
gut microbiota might result in increased
liver toxicity to the host in response to
acetaminophen, and the abundance of
p-cresol-producing bacteria varies
among individuals (Clayton et al., 2009).
Thus, understanding which members of
the gut microbiota have the capacity to
metabolize host-targeted xenobiotics is
vital for understanding the drug’s effec-
tiveness on an individual basis and for3 Elsevier Inc.predicting deleterious side effects.
Knowing that significant changes in the
microbial community’s gene expression
can occur in the absence of significant
changes in microbial community mem-
bership and structure encourages re-
searchers using 16S rRNA sequencing,
while very informative in certain situa-
tions, to also consider metatranscrip-
tomic profiling (McNulty et al., 2011).
Finding microbial signatures at the indi-
vidual taxa level, community-structure
level, or gene-expression level that corre-
late with drug efficacy or drug toxicity will
be crucial in order for researchers to
determine the mechanisms behind drug-
microbe-host interactions.
Modern pharmaceutical treatments
have a wide range of efficacy levels, and
the individuality of human gut micro-
biomes may play a significant role (Haiser
and Turnbaugh, 2012). The use of meta-
transcriptomics in these types of studies
promises to provide insights into the
mechanistic interplay between host-tar-
geted drugs and the microbial side of
ourselves, and understanding these inter-
actions may assist in development of
potent compounds to treat human
disease.
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